Hypercholesterolemia in Male Power Lifters Using Anabolic-Androgenic Steroids

Area of Science:

• Endocrinology
• Sports Medicine
• Cardiovascular Health

Background:

• Anabolic-androgenic steroids (AAS) are performance-enhancing drugs with known health risks.
• Previous research suggests AAS can negatively impact lipid profiles.
• Understanding the specific effects of AAS on cholesterol in athletes is crucial for risk assessment.

Purpose of the Study:

• To investigate the impact of anabolic-androgenic steroid (AAS) use on serum lipid profiles in male powerlifters.
• To determine the relationship between the duration of AAS use and changes in cholesterol levels.
• To assess the reversibility of AAS-induced lipid alterations after cessation of use.

Main Methods:

• Serum total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, and triglyceride levels were measured.
• Three groups of male powerlifters were studied based on AAS usage duration: short-term (8 weeks), medium-term (3 years), and long-term (8 years).
• Lipid profiles were assessed during AAS use and after cessation.

Main Results:

• Mean serum total cholesterol (TC) levels increased significantly in powerlifters using AAS.
• The increase in TC was primarily attributed to the low-density lipoprotein (LDL) fraction.
• Following cessation of AAS use, TC levels promptly decreased to near pre-steroid concentrations.
• Pre-steroid TC levels did not predict the magnitude of steroid-induced hypercholesterolemia.

Conclusions:

• Anabolic-androgenic steroid use leads to a significant, reversible increase in serum total cholesterol, mainly within the LDL fraction.
• The duration of AAS use did not correlate with the magnitude of hypercholesterolemia in this cohort.
• Individuals with low baseline cholesterol are not protected from developing AAS-induced hypercholesterolemia.